000283110 001__ 283110
000283110 005__ 20260102125119.0
000283110 0247_ $$2doi$$a10.1002/alz70855_106193
000283110 0247_ $$2ISSN$$a1552-5260
000283110 0247_ $$2ISSN$$a1552-5279
000283110 037__ $$aDZNE-2026-00006
000283110 082__ $$a610
000283110 1001_ $$0P:(DE-2719)9002968$$aSong, Xiaoxuan$$b0$$eFirst author$$udzne
000283110 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283110 245__ $$aAlpha‐Synuclein co‐pathology drives tau accumulation in Alzheimer's disease patients and iPSCs‐derived models
000283110 260__ $$c2025
000283110 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767354615_32512
000283110 3367_ $$033$$2EndNote$$aConference Paper
000283110 3367_ $$2BibTeX$$aINPROCEEDINGS
000283110 3367_ $$2DRIVER$$aconferenceObject
000283110 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283110 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283110 3367_ $$2ORCID$$aOTHER
000283110 520__ $$aBackground:The molecular basis for accelerated cognitive decline seen in Alzheimer's Disease (AD) cases presenting with cortical alpha-Synuclein co-pathology is not well understood. Mouse experiments have shown adverse interactions between tau (encoded by MAPT) and alpha-Synuclein (encoded by SNCA), but how this finding translates to humans from a genome-centered point of view remains unknown.Method:Whole genome sequencing was performed on 137 neuropathologically defined AD cases, 36 of which presented with neocortical alpha-Synuclein co-pathology (Braak stage 6). Polygenic risk scores were calculated. Single-nucleus RNA sequencing and Western Blot data were collected from post-mortem tissue. Transcriptomic and proteomic results were validated in the MSBB cohort (n >300). Cellular, molecular and epigenetic consequences were assessed in isogenic iPSCs-derived neurons carrying a triplication of SNCA (AST) or a normal SNCA copy number (CAS).Result:AD brains with alpha-Synuclein co-pathology had significantly higher polygenic risk scores for Parkinson's Disease, which could be partially explained by variants associated with higher expression of SNCA. Single-nucleus RNA sequencing and immunoblot analysis revealed a higher expression of MAPT and phosphorylated tau in alpha-Synuclein co-pathology cases. Protein and mRNA expression of MAPT and SNCA were positively correlated in the MSBB cohort. The employed iPSCs differentiation protocol accelerated neuronal maturation due to transient inhibition of EZH2. Day50 AST neurons exhibited significantly increased pathological tau and alpha-Synuclein at both the RNA and protein levels compared to CAS neurons. AST neurons also showed highly activated GSK3β and decreased PSD95 (post-synaptic protein) in the immunofluorescence and immunoblot analyses. ATAC profiles identified dysregulated accessibility in the cAMP signaling pathway, as well as pathways related to axon guidance, postsynaptic density, and calcium signaling, among others.Conclusion:We demonstrate that alpha-Synuclein co-pathology in AD is characterized by higher phosphorylated tau levels in patients and iPSC-derived neurons. Our results provide insights into the complex molecular processes through which alpha-Synuclein and tau synergistically drive dementia-related pathology.
000283110 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283110 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000283110 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283110 7001_ $$0P:(DE-2719)9002143$$ade Vecchi, Teodoro$$b1$$udzne
000283110 7001_ $$0P:(DE-2719)9000813$$aWidmann, Jeannine$$b2
000283110 7001_ $$0P:(DE-HGF)0$$aFierli, Federico$$b3
000283110 7001_ $$0P:(DE-HGF)0$$aRuf, Viktoria$$b4
000283110 7001_ $$0P:(DE-2719)9001127$$aTang, Qilin$$b5
000283110 7001_ $$0P:(DE-2719)2811333$$aArzberger, Thomas$$b6$$udzne
000283110 7001_ $$0P:(DE-HGF)0$$aRoeber, Sigrun$$b7
000283110 7001_ $$0P:(DE-2719)2810825$$aKöglsperger, Thomas$$b8$$udzne
000283110 7001_ $$0P:(DE-2719)2812263$$aWindl, Otto$$b9
000283110 7001_ $$0P:(DE-2719)2202037$$aHaass, Christian$$b10$$udzne
000283110 7001_ $$0P:(DE-HGF)0$$aWinkelmann, Juliane$$b11
000283110 7001_ $$0P:(DE-2719)2810441$$aHerms, Jochen$$b12$$udzne
000283110 7001_ $$0P:(DE-2719)2813904$$aStrübing, Felix$$b13$$eLast author$$udzne
000283110 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70855_106193$$gVol. 21, no. S1, p. e106193$$nS1$$pe106193$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283110 8564_ $$uhttps://pub.dzne.de/record/283110/files/DZNE-2026-00006.pdf$$yOpenAccess
000283110 8564_ $$uhttps://pub.dzne.de/record/283110/files/DZNE-2026-00006.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002968$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002143$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000813$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001127$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283110 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811333$$aExternal Institute$$b6$$kExtern
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2202037$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283110 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810441$$aExternal Institute$$b12$$kExtern
000283110 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2813904$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000283110 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283110 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000283110 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283110 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283110 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283110 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283110 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283110 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283110 9201_ $$0I:(DE-2719)1110001$$kAG Herms$$lTranslational Brain Research$$x0
000283110 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000283110 980__ $$aabstract
000283110 980__ $$aVDB
000283110 980__ $$aUNRESTRICTED
000283110 980__ $$ajournal
000283110 980__ $$aI:(DE-2719)1110001
000283110 980__ $$aI:(DE-2719)1111015
000283110 9801_ $$aFullTexts